Asani, Ben http://orcid.org/0000-0003-4809-2859
Holmberg, Olle
Schiefelbein, Johannes B.
Hafner, Michael
Herold, Tina
Spitzer, Hannah
Siedlecki, Jakob
Kern, Christoph
Kortuem, Karsten U.
Frishberg, Amit
Theis, Fabian J. http://orcid.org/0000-0002-2419-1943
Priglinger, Siegfried G. http://orcid.org/0000-0002-5580-612X
Funding for this research was provided by:
Helmholtz Association (ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01, ZT-I-PF-5-01)
Bundesministerium für Bildung und Forschung (031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A, 031L0210A)
Article History
Received: 11 August 2023
Revised: 28 June 2024
Accepted: 16 July 2024
First Online: 27 July 2024
Competing interests
: The following authors declare no Competing Non-Financial Interests but the following Competing Financial interests: Ben Asani receives speaker fees and study support from Novartis Pharma GmbH. Olle Holmberg has ownership in Helsing GmbH. Johannes Schiefelbein receives study support from Novartis Pharma GmbH. Tina Herold receives speaker honoraria and study support from Novartis Pharma GmbH and Bayer AG, speaker honoraria from Abbvie, and study support from Roche Holding AG. Christoph Kern has received travel fees from Bayer AG and Novartis Pharma GmbH. Consultant: Bayer AG. Karsten Kortuem has received speaker fees from Novartis Pharma GmbH, Bayer AG and Allergan. Jakob Siedlecki receives speaker honoraria and travel reimbursement from Carl Zeiss Meditec AG, Novartis Pharma GmbH, Bayer AG, Pharm-Allergan GmbH, Oculentis OSD Medical GmbH. Consultant: Bayer AG, Novartis Pharma GmbH, Pharm-Allergan GmbH. Travel reimbursement: Oertli AG. Siegfried Priglinger receives speaker and consultant honoraria from and has served on advisory boards for Abbott, Alcon, Geuder, Oculus, Schwind, STAAR, TearLab, Thieme Compliance, Ziemer, Zeiss; has received research funding from Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind and Zeiss. Fabian Theis consults for Immunai Inc., Singularity Bio B.V., CytoReason Ltd, and Omniscope Ltd, and has ownership interest in Dermagnostix GmbH and Cellarity. Hannah Spitzer and Michael Hafner declare no Competing Financial or Non-Financial Interests.
: Ethics committee of the medical faculty of the Ludwig-Maximilians-University of Munich gave ethical approval for this work.